Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases
- 24 January 2013
- journal article
- review article
- Published by Springer Nature in Clinical Reviews in Allergy & Immunology
- Vol. 47 (1) , 6-16
Abstract
Biological drugs targeting pro-inflammatory or co-stimulatory molecules or depleting lymphocyte subsets made a revolution in rheumatoid arthritis (RA) treatment. Their comparable efficacy in clinical trials raised the point of the heterogeneity of RA pathogenesis, suggesting that we are dealing with a syndrome rather than with a single disease. Several tumor necrosis factor-alpha (TNF-α) blockers are available, and a burning question is whether they are biosimilar or not. The evidence of diverse biological effects in vitro is in line with the fact that a lack of efficacy to one TNF-α agent does not imply a non-response to another one. As proteins, biologicals are potentially immunogenic. It has been recently raised that anti-drug antibodies (ADA) may affect their bioavailability and eventually the clinical efficacy through local formation of immune complexes and directly by preventing the interaction between the drug and TNF-α. Regular monitoring of drug and ADA levels appears the best way to tailor anti-TNF-α therapies. Owing to the pleiotropic characteristics of the target, anti-TNF-α blockers may affect several mechanisms beyond rheumatoid synovitis. As TNF-α plays a pivotal role in the induction of early atherosclerosis, treatment with TNF-inhibitors may modulate cholesterol handling, in particular, cholesterol efflux from macrophages. Side effects are a major issue because of the systemic TNF-α blocking action. The efficacy of an anti-C5 monoclonal antibody fused to a peptide targeting inflamed synovia in experimental arthritis opened the way for new strategies: Homing to the synovium of molecules neutralizing TNF would allow to maximize the therapeutic action avoiding the side effects.Keywords
This publication has 116 references indexed in Scilit:
- Crosstalk between reverse cholesterol transport and innate immunityTrends in Endocrinology & Metabolism, 2012
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisNew England Journal of Medicine, 2011
- Essential Role of Complement Mannose-Binding Lectin-Associated Serine Proteases-1/3 in the Murine Collagen Antibody-Induced Model of Inflammatory ArthritisThe Journal of Immunology, 2010
- Adipocyte Modulation of High-Density Lipoprotein CholesterolCirculation, 2010
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals of the Rheumatic Diseases, 2009
- Inflammation predicts accelerated brachial arterial wall changes in patients with recent-onset rheumatoid arthritisArthritis Research & Therapy, 2009
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- TRAF1–C5as a Risk Locus for Rheumatoid Arthritis — A Genomewide StudyNew England Journal of Medicine, 2007
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJournal of Clinical Investigation, 2007